U.S. Markets open in 4 hrs 20 mins
  • S&P Futures

    4,533.25
    -42.50 (-0.93%)
     
  • Dow Futures

    34,559.00
    -63.00 (-0.18%)
     
  • Nasdaq Futures

    15,687.50
    -301.00 (-1.88%)
     
  • Russell 2000 Futures

    2,156.20
    -49.00 (-2.22%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    47,620.42
    -1,484.68 (-3.02%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.

  • The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.

  • Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.

  • Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.

  • Related: Selecta In-Licenses Rights To IgG Protease Platform.

  • Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.